INVO Fertility, Inc. (IVF): Nasdaq/NYSE listing notice — INVO gets Nasdaq extension until May 22, 2023 to regain compliance with equity rule

(the “Stockholders’ Equity Requirement). In the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, the Company reported stockholders’ equity of $1,287,224, which is below the Stockholders’ Equity Requirement for continued listing. Additionally, as of the date of the Notice, the Company did not meet either of the alternative Nasdaq

January 18, 2023 letter from Nasdaq granting an extension of time to regain compliance with Nasdaq Listing Rule 5550(b) until May 22, 2023. Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On November 23, 2022, INVO Bioscience, Inc. (the “Company”) received notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires companies listed on